•
Sep 30, 2021
Inozyme Q3 2021 Earnings Report
Reported financial results for the third quarter ended September 30, 2021, and provided recent business highlights.
Key Takeaways
Inozyme Pharma reported a net loss of $14.3 million for Q3 2021, with cash, cash equivalents, and investments totaling $125.3 million as of September 30, 2021. The company is on track to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021, with preliminary data expected in the first half of 2022.
On track to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021.
Preliminary biomarker and safety data expected in the first half of 2022.
Cash, cash equivalents, and investments were $125.3 million as of September 30, 2021.
Existing cash is expected to fund operations into the first quarter of 2023.